L'histone méthyltransférase SETD2 est responsable de la triméthylation de la lysine 36 sur l'histone H3. Cette marque épigénétique (H3K36me3) est notamment cruciale pour la régulation de la transcription, l'épissage et la réparation de l'ADN. De nombreuses études ont montré que SETD2 est un suppresseur de tumeur fréquemment muté dans le cancer. Cep...
Published in Digestive diseases and sciences
Pancreatic cancer is one of the most fatal malignancies, as approximately 80% of patients are at advanced stages by the time of diagnosis. The main reason for the poor overall survival is late diagnosis that is partially due to the lack of tools for early-stage detection. In addition, there are several challenges in evaluating response to treatment...
Published in Journal of cancer research and clinical oncology
The effect of immuno-chemotherapy on patients with advanced non-small-cell lung cancer (NSCLC) harboring oncogenic mutations remains poorly understood. This study aimed to characterize the efficacy of immuno-chemotherapy and determine the optimal treatment strategy for such patients. We conducted this retrospective cohort study on patients with NSC...
Chez l'Homme, SET Domain containing 2 (SETD2) est la principale histone méthyltransférase responsable de la triméthylation de la lysine 36 de l'histone H3 (H3K36) pour donner la marque épigénétique H3K36me3. Cette enzyme fait partie de la famille des histone méthyltransférases à domaine SET et catalyse le transfert d'un groupe méthyl sur la lysine ...
Published in International journal of biological macromolecules
Liquid-liquid phase separation (LLPS) drives the formation of extensive membrane-less compartments to regulate various cellular biological activities both physiologically and pathologically. It has been widely accepted that LLPS is closely related to amyloid diseases and increasing reports have linked this phenomenon to cancers. Mutations of tumor ...
Published in Dermatology
New therapeutic avenues and emerging topical and laser therapies could improve outcomes in SK patients.
Published in Cancer metastasis reviews
RAS proteins control a number of essential cellular processes as molecular switches in the human body. Presumably due to their important signalling role, RAS proteins are among the most frequently mutated oncogenes in human cancers. Hence, numerous efforts were done to develop appropriate therapies for RAS-mutant cancers in the last three decades. ...
Published in World Journal of Clinical Oncology
Lung cancer remains the leading cause of cancer-related deaths worldwide. The treatment of non-small cell lung cancer (NSCLC), which accounts for a vast majority of lung cancers, has shifted to personalized, targeted therapy following discoveries of several targetable oncogenic mutations. Targeting of specific mutations has improved outcomes in man...
Published in Advances in experimental medicine and biology
Cutaneous melanoma is one of the most aggressive types of cancer, presenting the highest potential to form metastases, both locally and distally, which are associated with high death rates of melanoma patients. A high somatic mutation burden is characteristic of these tumours, with most common oncogenic mutations occurring in the BRAF, NRAS and NF1...
Published in La Revue de medecine interne
Apart from myeloma, primary prophylaxis of venous thromboembolism (VTE) in ambulatory cancer patients treated with chemotherapy is underused, despite its proven benefit for pancreatic cancer and to a lesser extent for lung cancer. This prophylaxis has been showed to be effective for myeloma, pancreas but in absolute numbers these cancers lead to a ...
